2020 Virtual ESMO Review

 

Videos
05:09

2020 Virtual ESMO Review

2020 ESMO Update on R/R DLBCL: Does AUTO3 + Pembro Induce CRs? What Are the Outcomes of Pts With HIV Receiving High-Dose Chemotherapy?

FEATURING Jennifer Amengual
  • 19 views
  • December 3, 2020
07:49

2020 Virtual ESMO Review

2020 ESMO Update on R/R cHL: How Effective Is Brentuximab Vedotin?

FEATURING Jennifer Amengual
  • 55 views
  • December 3, 2020
06:52

2020 Virtual ESMO Review

2020 ESMO Update on Non-Hodgkin Lymphomas: Does BETi CC-90010 Lead to Clinical Responses in R/R DLBCL? How Effective Is LSD1 Inhibitor CC-90011 MZL?

FEATURING Jennifer Amengual
  • 17 views
  • December 3, 2020
07:33

2020 Virtual ESMO Review

2020 ESMO Update on Targeted Therapy in NSCLC: Does ADAURA Trial Suggest Clinically Meaningful Improvement in CNS DFS With Osimertinib? Does Heavily Pretreated KRAS G12C-Mutant NSCLC Respond to Sotorasib?

FEATURING Ibiayi Dagogo-Jack
  • 177 views
  • November 25, 2020
05:44

2020 Virtual ESMO Review

2020 ESMO Update on Targeted Therapy in NSCLC: Can We Safely Combine Amivantamab + Lazertinib in Advanced EGFR+ Disease?

FEATURING Ibiayi Dagogo-Jack
  • 29 views
  • November 25, 2020
06:52

2020 Virtual ESMO Review

2020 ESMO Update on UC: Does 1L Durvalumab +/- Tremelimumab Improve OS vs. SoC Chemo in Unresectable Advanced UC? Can Sacituzumab Govitecan Change Practice in mUC?

FEATURING Manojkumar Bupathi
  • 47 views
  • November 16, 2020
08:30

2020 Virtual ESMO Review

2020 ESMO Update on RCC: Is IO + TKI Option Effective in Advanced Disease? Is ctDNA Analysis Feasible and Highly Concordant With Tissue Genomic Analysis and Can It Guide Treatment Selection in mRCC?

FEATURING Manojkumar Bupathi
  • 213 views
  • November 16, 2020
  • 2
07:47

2020 Virtual ESMO Review

2020 ESMO Update on Advanced UC: Does the Addition of Avelumab 1L Maintenance to BSC in Advanced Disease Affect on Clinically Relevant PROs? Is There More PFS/OS Benefit Upon the Addition of Pembro to Chemo?

FEATURING Manojkumar Bupathi
  • 74 views
  • November 16, 2020
11:16

2020 Virtual ESMO Review

2020 ESMO Update on ALK+ NSCLC: PFS Data With Lorlatinib vs. Crizotinib - Should We Consider Lorlatinib a New 1L Option?

FEATURING Ibiayi Dagogo-Jack
  • 233 views
  • November 11, 2020
  • 2
20:42

2020 Virtual ESMO Review

ESMO 2020 Update on mPC: How Beneficial Is Abiraterone+/-Ipatasertib for rPFS? Does PSMA-Targeting AMG160 BiTe Offer Good Duration of Response? Can Metformin Delay Disease Progression?

FEATURING Tanya Barauskas Dorff
  • 85 views
  • November 9, 2020
33:00

Total Health

Will COVID-19 Leave Its Mark on Cancer Care?

FEATURING Gilberto Lopes
  • 1,814 views
  • November 6, 2020
  • 6
08:53

2020 Virtual ESMO Review

2020 ESMO Updates on Pembrolizumab & Cemiplimab: Can mNSCLC Be Cured With Immunotherapy?

FEATURING Martin Dietrich
  • 599 views
  • November 4, 2020
  • 5
06:15

2020 Virtual ESMO Review

2020 ESMO First Results from PIONeeR Project on Biomarkers in Advanced NSCLC: Can Biomarker Analysis Predict Response/Resistance to ICIs?

FEATURING Martin Dietrich
  • 515 views
  • November 4, 2020
  • 1
09:56

2020 Virtual ESMO Review

2020 ESMO Updates in Lung Cancer: Does 1L Nivolumab–Ipilimumab Boost Unresectable Mesothelioma OS? Did the PACIFIC Trial Demonstrate Durable Benefit With Durvalumab After cCRT in Stage 3 NSCLC?

FEATURING Martin Dietrich
  • 616 views
  • November 4, 2020
  • 1
07:30

2020 Virtual ESMO Review

2020 ESMO Update on MBC: Is There OS Benefit to Alpelisib + Fulvestrant in PI3KCA-Mutated HR+ MBC? Does Sacituzumab Govitecan Improve PFS & OS Over Standard Chemotherapy in mTNBC?

FEATURING Jennifer Crozier
  • 121 views
  • November 4, 2020
  • 1
10:12

2020 Virtual ESMO Review

2020 ESMO Update on MBC: Does the Addition of Tamoxifen to Abemaciclib Provide OS Improvement in HR+ Disease? Is TMB Associated With Improved Outcomes With 1L Atezolizumab + Nab-Paclitaxel in mTNBC?

FEATURING Jennifer Crozier
  • 523 views
  • November 4, 2020
  • 1
08:19

2020 Virtual ESMO Review

2020 ESMO Update on Immune Checkpoint Inhibitors in eTNBC: Does the Addition of Atezolizumab to Chemotherapy Improve pCR Rate in Neoadjuvant Setting?

FEATURING Lee Schwartzberg
  • 379 views
  • November 4, 2020
  • 4
06:06

2020 Virtual ESMO Review

2020 ESMO Update on CDK 4/6 in Adjuvant HR+, HER2- EBC: Does the Addition of Abemaciclib to Hormonal Therapy Reduce the Risk of Cancer Recurrence?

FEATURING Lee Schwartzberg
  • 184 views
  • November 4, 2020
07:46

2020 Virtual ESMO Review

2020 ESMO Update on CDK 4/6 in Adjuvant HR+, HER2- EBC: How Does Two Years of Adjuvant Palbociclib With ET Compare to ET Alone?

FEATURING Lee Schwartzberg
  • 200 views
  • November 4, 2020
  • 1
13:27

2020 Virtual ESMO Review

2020 ESMO Update on mPDAC: Does the Addition of Dual Immune Checkpoint Inhibitors to Gem and Nab-p Result in Improved OS, PFS, or ORR?

FEATURING Louise Connell
  • 229 views
  • November 4, 2020
  • 1
08:07

2020 Virtual ESMO Review

2020 ESMO Update on Metastatic Pancreatic Cancer: What Does the QoliXane Trial Data Suggest on Time to Deterioration of QoL in Patients Treated With 1L Nab-Paclitaxel?

FEATURING Louise Connell
  • 64 views
  • November 4, 2020